References

Unresolved reference

External reference

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

10.1016/s2213-2600(20)30079-5 · 2020 · External reference

Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis.

10.1371/journal.pone.0251170 · 2021 · External reference

Seroprevalence of latent cytomegalovirus infection among elderly Thais

2012 · External reference

Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials

10.1093/cid/ciw668 · 2017 · External reference

Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome

10.1016/j.jinf.2007.10.005 · 2008 · External reference

Cytomegalovirus reactivation in critically-ill Coronavirus Disease 2019 patients: A case series of 11 patients.

10.1016/j.idcr.2022.e01402 · 2022 · External reference

Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality.

10.1007/s00134-022-06716-y · 2022 · External reference

Cytomegalovirus infection in critically ill patients: a systematic review.

10.1186/cc7875 · 2009 · External reference

Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit.

10.1097/ccm.0b013e3181a3aa43 · 2009 · External reference

Occult herpes family viral infections are endemic in critically ill surgical patients.

10.1097/01.ccm.0000070222.11325.c4 · 2003 · External reference

Cytomegalovirus infection in critically ill patients: associated factors and consequences.

10.1378/chest.127.1.233 · 2005 · External reference

Does reactivation of cytomegalovirus contribute to severe COVID-19 disease.

10.1186/s12979-021-00218-z · 2021 · External reference

Cytomegalovirus infection in critically ill patients with COVID-19.

10.1016/j.jinf.2021.07.004 · 2021 · External reference

SARS-CoV-2 and Cytomegalovirus co-Infections-a case series of critically ill patients.

10.3390/jcm10132792 · 2021 · External reference

Fatal cytomegalovirus pneumonia in a critically ill patient with COVID-19.

10.1002/rcr2.801 · 2021 · External reference

The role of bronchoscopy in patients with SARS-CoV-2 pneumonia.

10.1183/23120541.00165-2021 · 2021 · External reference

Cytomegalovirus (CMV) DNA quantitation in bronchoalveolar lavage fluid from hematopoietic stem cell transplant recipients with CMV pneumonia.

10.1093/infdis/jix048 · 2017 · External reference

Dexamethasone in hospitalized patients with Covid-19

10.1056/nejmoa2021436 · 2021 · External reference

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial

10.1001/jama.2020.17021 · 2020 · External reference

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial

10.1183/13993003.02808-2020 · 2020 · External reference

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure.

10.1007/bf01709751 · 1996 · External reference

Co-infections and superinfections in COVID-19 critically ill patients are associated with CT imaging abnormalities and the worst outcomes.

10.3390/diagnostics12071617 · 2022 · External reference

Tocilizumab in hospitalized patients with severe Covid-19 pneumonia

10.1056/nejmoa2028700 · 2021 · External reference

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.

10.1016/s2213-2600(21)00331-3 · 2021 · External reference

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

10.1016/s0140-6736(22)01109-6 · 2022 · External reference

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

10.1016/s0140-6736(21)00676-0 · 2021 · External reference

Tofacitinib in patients hospitalized with Covid-19 pneumonia

10.1056/nejmoa2101643 · 2021 · External reference

Baricitinib plus remdesivir for hospitalized adults with Covid-19

10.1056/nejmoa2031994 · 2021 · External reference

Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial.

10.1186/s12879-021-06045-3 · 2021 · External reference

Outcomes of cytomegalovirus viremia treatment in critically ill patients with COVID-19 infection.

10.1093/ofid/ofac286 · 2022 · External reference

Unresolved reference

External reference

Living guidance for clinical management of COVID-19. 23

2021 · External reference